NASDAQ$VNDA
Vanda Pharmaceuticals Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported a decrease in total revenues and net income compared to the same quarter last year, while making progress on regulatory filings and intellectual property litigation.
Vanda Pharmaceuticals reported Q4 2022 total revenues of $64.5 million, a 5% decrease compared to Q4 2021. Net income was $6.9 million, slightly lower than the $7.1 million reported in the same quarter of the previous year. The company is pursuing regulatory approvals for HETLIOZ® and preparing for an NDA submission for tradipitant.
- Total revenues for Q4 2022 were $64.5 million, a 5% decrease year-over-year.
- HETLIOZ® net product sales decreased by 9% to $40.1 million due to reimbursement challenges.
- Fanapt® net product sales increased by 2% to $24.4 million.
- Net income was $6.9 million, slightly lower compared to $7.1 million in Q4 2021.
Headline financials
Revenue & EPS history
Vanda · Revenue · Quarterly
$64.5M
Revenue by segment
Vanda · $64.5M total across 2 segments · Q4 2022
- HETLIOZ$40.1M-9.0%62.2%
- Fanapt$24.4M+1.8%37.8%
Forward guidance
Due to uncertainties surrounding the U.S. market for HETLIOZ® as a result of the ongoing HETLIOZ® patent litigation, Vanda is unable to provide 2023 financial guidance at this time.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
-0.7%
Avg return
Earnings day
+0.0%
Avg return
5 days after
+1.9%
Avg return
30 days after
45%
29 / 65 earnings
Positive
+24.8%
Q2 2019
Best reaction
-23.7%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -10.5% | -13.8% | -19.1% | |
| Q4 2025 | -17.6% | -16.6% | +18.6% | |
| Q3 2025 | -0.9% | -1.4% | +21.4% | |
| Q1 2025 | -3.9% | -9.1% | +5.3% | |
| Q4 2024 | -6.0% | -3.2% | +6.0% | |
| Q3 2024 | +4.8% | +11.5% | +1.0% | |
| Q2 2024 | -3.4% | -9.1% | -9.4% | |
| Q1 2024 | -8.6% | -7.8% | +11.7% | |
| Q4 2023 | +9.1% | +16.1% | +3.8% | |
| Q3 2023 | -23.7% | -23.0% | -15.1% | |
| Q2 2023 | -8.8% | -13.4% | -14.3% | |
| Q1 2023 | +7.0% | +7.9% | -5.6% | |
| Q4 2022 | -4.6% | -4.5% | -18.0% | |
| Q3 2022 | -4.8% | -0.2% | +2.5% | |
| Q2 2022 | -1.2% | +0.9% | -0.5% | |
| Q1 2022 | -6.2% | -0.1% | -0.8% | |
| Q4 2021 | -5.0% | -15.2% | -14.5% | |
| Q3 2021 | -11.8% | -11.9% | -21.2% | |
| Q2 2021 | -7.4% | -12.4% | -10.5% | |
| Q1 2021 | +5.1% | +7.2% | +8.6% | |
| Q4 2020 | +20.5% | +17.6% | +15.5% | |
| Q3 2020 | +3.8% | +3.5% | +17.2% | |
| Q2 2020 | +6.2% | +10.2% | -5.3% | |
| Q1 2020 | -4.4% | +0.4% | -2.5% | |
| Q4 2019 | -3.7% | -6.2% | -20.5% | |
| Q3 2019 | +7.6% | +10.2% | +29.4% | |
| Q2 2019 | +24.8% | +21.2% | +11.4% | |
| Q1 2019 | -3.1% | +1.3% | -9.9% | |
| Q4 2018 | +9.3% | +14.7% | -0.7% | |
| Q3 2018 | +16.7% | +12.5% | +37.2% | |
| Q2 2018 | +4.1% | +2.4% | -7.3% | |
| Q1 2018 | +10.6% | +11.0% | +25.1% | |
| Q4 2017 | +6.6% | +7.9% | +4.7% | |
| Q3 2017 | -16.8% | -16.5% | -11.7% | |
| Q2 2017 | +7.1% | +3.5% | +11.3% | |
| Q1 2017 | -0.3% | -3.3% | -8.0% | |
| Q4 2016 | -0.7% | +2.7% | -1.7% | |
| Q3 2016 | -8.4% | -2.3% | +4.7% | |
| Q2 2016 | +2.7% | +8.5% | +36.9% | |
| Q1 2016 | +3.9% | — | — | |
| Q4 2015 | -0.6% | — | — | |
| Q3 2015 | -9.5% | — | — | |
| Q2 2015 | +8.3% | — | — | |
| Q1 2015 | +7.2% | — | — | |
| Q4 2014 | -12.7% | — | — | |
| Q3 2014 | +8.3% | — | — | |
| Q2 2014 | -11.3% | — | — | |
| Q1 2014 | -20.2% | — | — | |
| Q4 2013 | +7.2% | — | — | |
| Q3 2013 | -3.3% | — | — | |
| Q2 2013 | +4.0% | — | — | |
| Q1 2013 | +7.6% | — | — | |
| Q4 2012 | +0.8% | — | — | |
| Q3 2012 | -6.2% | — | — | |
| Q2 2012 | +1.0% | — | — | |
| Q1 2012 | -0.4% | — | — | |
| Q4 2011 | +6.5% | — | — | |
| Q4 2009 | +6.5% | — | — | |
| Q3 2011 | -2.2% | — | — | |
| Q3 2010 | -2.2% | — | — | |
| Q4 2010 | -10.9% | — | — | |
| Q2 2011 | -10.9% | — | — | |
| Q2 2010 | -10.9% | — | — | |
| Q1 2011 | +1.7% | — | — | |
| Q1 2010 | +7.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro